Dog Vaccines Market Research/Analysis Report 2026: $5.44 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Dublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "Dog Vaccines Market Report 2026" has been added to ResearchAndMarkets.com's offering.
The dog vaccines market has demonstrated significant growth, with its value projected to expand from $3.8 billion in 2025 to $4.07 billion in 2026, registering a compound annual growth rate (CAGR) of 7.2%. This uplift stems from an increase in the global dog population, heightened awareness of canine diseases, and the introduction of novel vaccine formulations. The advancement of veterinary healthcare infrastructure and a rise in infectious canine disease prevalence further contribute to this trend.
Looking ahead, the market is anticipated to escalate to $5.44 billion by 2030, at a CAGR of 7.5%. Key drivers include developments in recombinant and DNA vaccines, a stronger emphasis on canine preventive healthcare, and expanded veterinary immunization initiatives. Notable trends include the rise of multivalent vaccines and increased preventive care adoption, fostering expansion in both pediatric and adult canine vaccine programs across veterinary clinics.
Zoonotic diseases-which are infectious diseases transmissible between animals and humans-highlight the critical role dog vaccines play in enhancing public health. According to the Council on Foreign Relations, these diseases account for significant human morbidity and mortality globally. With zoonoses responsible for millions of human fatalities and billions of disease episodes annually, the dog vaccines market is poised for continued growth as it addresses these public health challenges.
Key market players are investing in next-generation vaccine technologies, such as RNA-based and recombinant vaccines, to boost immune response and ensure extended protection. Merck & Co. Inc.'s MSD Animal Health achieved a significant milestone in 2024 with the USDA approval of Nobivac NXT Canine Influenza Virus, exemplifying innovation in canine viral protection strategies.
Strategic acquisitions further amplify market dynamics, as evident from Boehringer Ingelheim's acquisition of Saiba Animal Health AG. This move expands their R&D capabilities in the animal health domain with a focus on therapeutic vaccines for chronic conditions in pets. Leading companies in the field include Vetoquinol S.A., Boehringer Ingelheim GmbH, Ceva Sante Animale, Heska Corporation, and several others. These firms contribute to a comprehensive array of vaccine solutions, enhancing global canine health.
Regionally, Asia-Pacific led the market in 2025, reflecting diverse growth across multiple international markets including North America and Europe. Challenges such as tariffs have impacted import costs for high-tech formulations in these regions, spurring local innovation and manufacturing in response.
Reasons to Purchase:
Key Market Insights:
Major Trends
Companies Featured
Key Attributes:
For more information about this report visit https://www.researchandmarkets.com/r/mh1wn9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment